Apogee Therapeutics (NASDAQ:APGE) Posts Quarterly Earnings Results, Hits Estimates

Apogee Therapeutics (NASDAQ:APGE) posted its quarterly earnings data on Monday. The company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60), Yahoo Finance reports.

Apogee Therapeutics Trading Down 0.6 %

APGE traded down $0.25 on Wednesday, hitting $44.16. 68,212 shares of the company’s stock traded hands, compared to its average volume of 535,140. The company’s 50 day simple moving average is $43.02 and its 200-day simple moving average is $47.60. The firm has a market cap of $2.58 billion and a price-to-earnings ratio of -8.46. Apogee Therapeutics has a one year low of $14.19 and a one year high of $72.29.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Bank of America assumed coverage on Apogee Therapeutics in a research note on Friday, May 10th. They issued a “buy” rating and a $80.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and issued a $87.00 price objective on shares of Apogee Therapeutics in a research note on Monday, May 13th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $73.00.

Insider Activity at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $37.26, for a total value of $558,900.00. Following the sale, the chief executive officer now owns 1,474,487 shares of the company’s stock, valued at approximately $54,939,385.62. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $37.26, for a total value of $558,900.00. Following the sale, the chief executive officer now owns 1,474,487 shares of the company’s stock, valued at approximately $54,939,385.62. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Carl Dambkowski sold 5,995 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total value of $225,412.00. Following the completion of the sale, the insider now directly owns 294,793 shares in the company, valued at approximately $11,084,216.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 68,330 shares of company stock valued at $2,707,426. 36.10% of the stock is owned by company insiders.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.